Supernus Pharma (NASDAQ:SUPN) announced top-line results from P304, its Phase 3 study of SPN-812 in adolescents with attention deficit hyperactivity disorder (ADHD). SPN-812 is a non-stimulant serotonin norepinephrine...
Transcranial magnetic stimulation (TMS) pioneer, Neuronetics (NASDQ:STIM), received reimbursement approval from Japan’s Central Social Insurance Medical Council for its NeuroStar Advanced Therapy for the treatment...
Titan Pharmaceuticals (NASDAQ:TTNP) executed a service agreement with AppianRx, a specialty healthcare solutions company, to provide a full suite of patient support services related to Titan’s Probuphine implant, a...
Closely-held Lutronic Vision retained professor Robyn Guymer, a world-renowned age-related macular degeneration (AMD) expert and key opinion leader, to serve as the principal investigator for its planned pilot clinical...
BeyondSpring (NASDAQ: BYSI) will present a promising new strategy for cancer treatment involving the ability of its lead asset, Plinabulin, to positively shift the balance of macrophage phenotypes for a beneficial anti...
BeyondSpring (NASDAQ: BYSI) will present novel data relevant to predictive biomarkers for patient selection for its lead asset, Plinabulin, at the 2019 American Association for Cancer Research (AACR) annual meeting in...
Gritstone Oncology (NASDAQ:GRTS) dosed the first patient with its personalized immunotherapy candidate targeting the patient’s tumor-specific neoantigens, called GRANITE-001. The Phase 1/2 clinical study is evaluating...
Biogen (NASDAQ:BIIB) and partner Eisai are discontinuing two global Phase 3 trials to evaluate the efficacy and safety of aducanumab in Alzheimer’s disease (AD). Aducanumab is a monoclonal antibody designed to slow AD...
RTI Surgical (NASDAQ:RTIX) has enrolled the first patient in a clinical trial testing the safety and performance of its Fortilink interbody fusion device. Fortilink is designed to promote spinal fusion after surgery...
Altimmune’s (NASDAQ:ALT) intranasal influenza vaccine, NasoVAX, demonstrated a seroprotective antibody response in all subjects who received the vaccine more than one year ago. The Phase 2a trial of NasoVAX was...
Tiziana Life Sciences (NASDAQ:TLSA, AIM:TILS) submitted an IND to the FDA for its enteric-coated capsules of Foralumab, an anti-CD3 monoclonal antibody. Foralumab, believed to induce an anti-inflammatory response by...
Aptevo Therapeutics (NASDAQ:APVO) began dosing subjects in its Phase 1 trial for APVO210, a targeted cytokine immunotherapy. APVO210 is a modified form of the cytokine, IL-10, that suppresses inflammation without...
GeoVax Labs (OTCQB:GOVX) published research showing that a single intramuscular dose of its Ebola vaccine, GEO-EM01, provided 100% protection in rhesus macaques challenged with a lethal dose of Ebola virus. GEO-EM01...
Puma Biotech (NASDAQ:PBYI) received approval to market neratinib in Australia via its licensing partner, Specialised Therapeutics Asia, who has also submitted an application for regulatory approval in Singapore...
Dare Bioscience’s (NASDAQ:DARE) DARE-VVA1, a proprietary formulation of tamoxifen designed for vaginal delivery, showed significant improvements in reducing vaginal pH and dryness in patients with vulvar and vaginal...
Aerpio Pharmaceuticals (NASDAQ:ARPO) lead candidate, AKB-9778, failed to meet its primary endpoint in its Phase 2b trial for moderate-to-severe non-proliferative diabetic retinopathy (NPDR). Compared to placebo, twice...
Dermira’s (NASDAQ:DERM) Phase 2b dose-ranging study of lebrikizumab in atopic dermatitis demonstrated that all three doses achieved greater improvements in the Eczema Area and Severity Index score, compared with placebo...
Karyopharm Therapeutics (NASDAQ:KPTI) announced that the FDA has extended its review of the company’s NDA for selinexor by three months. Selinexor’s NDA is currently under priority review for its use in combination with...
Soleno Therapeutics (NASDAQ:SLNO) reported that the Data Safety Monitoring Board (DSMB) recommended continuation of the company’s Phase 3 trial in Prader-Willi Syndrome (PWS) patients, without any changes. The...
Moleculin Biotech (NASDAQ:MBRX) has treated the first patients in its European Phase 1/2 clinical trial of Annamycin for relapsed and refractory acute myeloid leukemia (AML). The company also submitted a request to the...
Akebia Therapeutics (NASDAQ:AKBA) vadadustat met its primary endpoint in two pivotal Phase 3 clinical trials for anemia due to chronic kidney disease (CKD). The trials compared the safety and efficacy of vadadustat to...